President Trump announced on Tuesday via Truth Social that imported generic drugs will face a 100% tariff beginning in August 2028, escalating to 200% in 2029, unless manufacturers relocate production to the United States. The move is framed as a penalty to force the reshoring of generic pharmaceutical manufacturing, a sector largely dominated by overseas factories in Europe and India.
The administration has yet to release an official policy implementing the tariffs, but the threat signals a significant escalation in Trump's trade war on pharmaceuticals. If enacted, the tariffs would put generic medicines on par with branded drugs, which are already set to face tariffs as high as 100% by the end of this month. The White House had previously exempted generics from such measures.
Trump has made drug pricing a cornerstone of his efforts to address cost-of-living concerns, a key issue for voters ahead of the midterm elections. He has long criticized pharmaceutical companies for charging Americans far more than patients in other wealthy nations. To bridge that gap, his administration has employed tariffs and pursued most-favored-nation pricing agreements, where drugmakers agree not to exceed prices paid in comparable countries.
Last month, the U.S. Trade Representative launched an investigation into Germany's pharmaceutical pricing system, which could lead to retaliatory tariffs. In December, the administration struck a trade deal with the United Kingdom that exempts UK pharmaceuticals from U.S. tariffs in exchange for Britain paying more for medicines. These moves are part of a broader strategy to leverage trade policy to lower domestic drug costs.
The generic drug industry, represented by the Association for Accessible Medicines (AAM), expressed caution. AAM President and CEO John Murphy III called for more details on the policy, stating, “We need to understand more the specifics of the policy, but the generics industry is committed to pursuing policies that support and stabilize both the industry and the access necessary to ensure patients have reliable options for affordable medicines.” He added that the industry has legislative and regulatory solutions to address market deficiencies and looks forward to dialogue with the administration and Congress to restore growth and prioritize generics as a national security asset.
The announcement has raised concerns among GOP senators who are wary of the economic impact of new tariffs, especially as affordability fears mount. Some have drawn parallels to Trump's recent threats of tariffs on Canadian goods over wildfire smoke, which scientists attribute to climate change. The president's aggressive trade stance could complicate his party's midterm messaging on the economy.
Industry analysts warn that upending the generic drug supply chain could lead to shortages and higher prices for consumers, contradicting Trump's stated goal of lowering costs. The 2028 deadline gives manufacturers a window to adapt, but the escalating tariff rates create pressure for rapid relocation. Critics argue that domestic production faces significant barriers, including regulatory hurdles and higher labor costs, which the AAM has urged the administration to address.
Trump's latest move is part of a pattern of using tariffs as leverage in trade disputes, from threats against Iran over Strait of Hormuz attacks to renegotiating deals with allies. The president's focus on reshoring essential industries like pharmaceuticals aligns with his broader America First agenda, but the feasibility and consequences remain uncertain.
